MA26947A1 - Prodrogues pour ligands recepteurs de nmda - Google Patents
Prodrogues pour ligands recepteurs de nmdaInfo
- Publication number
- MA26947A1 MA26947A1 MA27052A MA27052A MA26947A1 MA 26947 A1 MA26947 A1 MA 26947A1 MA 27052 A MA27052 A MA 27052A MA 27052 A MA27052 A MA 27052A MA 26947 A1 MA26947 A1 MA 26947A1
- Authority
- MA
- Morocco
- Prior art keywords
- products
- nmda receptor
- receptor ligands
- ligands
- nmda
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00117918 | 2000-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26947A1 true MA26947A1 (fr) | 2004-12-20 |
Family
ID=8169594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27052A MA26947A1 (fr) | 2000-08-21 | 2003-02-21 | Prodrogues pour ligands recepteurs de nmda |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6407235B1 (https=) |
| EP (1) | EP1313703B1 (https=) |
| JP (1) | JP4162991B2 (https=) |
| KR (1) | KR100589991B1 (https=) |
| CN (1) | CN1227230C (https=) |
| AR (1) | AR030373A1 (https=) |
| AT (1) | ATE386022T1 (https=) |
| AU (2) | AU8589401A (https=) |
| BR (1) | BR0113348A (https=) |
| CA (1) | CA2419279C (https=) |
| CY (1) | CY1107937T1 (https=) |
| CZ (1) | CZ303319B6 (https=) |
| DE (1) | DE60132782T2 (https=) |
| DK (1) | DK1313703T3 (https=) |
| EC (1) | ECSP034489A (https=) |
| EG (1) | EG24293A (https=) |
| ES (1) | ES2299508T3 (https=) |
| HR (1) | HRP20030125B1 (https=) |
| HU (1) | HU229802B1 (https=) |
| IL (1) | IL154254A0 (https=) |
| JO (1) | JO2289B1 (https=) |
| MA (1) | MA26947A1 (https=) |
| MX (1) | MXPA03001311A (https=) |
| MY (1) | MY136065A (https=) |
| NO (1) | NO324941B1 (https=) |
| NZ (1) | NZ523990A (https=) |
| PA (1) | PA8525601A1 (https=) |
| PE (1) | PE20020291A1 (https=) |
| PL (1) | PL204215B1 (https=) |
| PT (1) | PT1313703E (https=) |
| RS (1) | RS51467B (https=) |
| RU (1) | RU2272027C2 (https=) |
| SI (1) | SI1313703T1 (https=) |
| WO (1) | WO2002016321A1 (https=) |
| ZA (1) | ZA200300894B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ520657A (en) * | 2000-03-21 | 2004-11-26 | Procter & Gamble | Heterocyclic side chain containing, N-substituted metalloprotease inhibitors |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| JP2009521424A (ja) * | 2005-12-19 | 2009-06-04 | メチルジーン インコーポレイテッド | 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤 |
| US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| MX2009006542A (es) | 2006-12-19 | 2009-06-30 | Methylgene Inc | Inhibidores de histona desacetilasa y sus profarmacos. |
| RS58991B1 (sr) | 2013-11-05 | 2019-08-30 | Astrazeneca Ab | Prolekovi nmda antagonista |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995020587A1 (en) * | 1994-01-31 | 1995-08-03 | Pfizer Inc. | Neuroprotective chroman compounds |
| DE4410822A1 (de) | 1994-03-24 | 1995-09-28 | Schering Ag | Neue Piperidin-Derivate |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
-
2001
- 2001-08-16 PE PE2001000820A patent/PE20020291A1/es not_active Application Discontinuation
- 2001-08-16 PA PA20018525601A patent/PA8525601A1/es unknown
- 2001-08-16 US US09/931,431 patent/US6407235B1/en not_active Expired - Lifetime
- 2001-08-17 AR ARP010103939A patent/AR030373A1/es active IP Right Grant
- 2001-08-17 MY MYPI20013876A patent/MY136065A/en unknown
- 2001-08-19 JO JO2001136A patent/JO2289B1/en active
- 2001-08-20 DE DE60132782T patent/DE60132782T2/de not_active Expired - Lifetime
- 2001-08-20 JP JP2002521197A patent/JP4162991B2/ja not_active Expired - Fee Related
- 2001-08-20 RU RU2003107572/04A patent/RU2272027C2/ru not_active IP Right Cessation
- 2001-08-20 MX MXPA03001311A patent/MXPA03001311A/es active IP Right Grant
- 2001-08-20 NZ NZ523990A patent/NZ523990A/en not_active IP Right Cessation
- 2001-08-20 CN CNB01814361XA patent/CN1227230C/zh not_active Expired - Fee Related
- 2001-08-20 ES ES01965201T patent/ES2299508T3/es not_active Expired - Lifetime
- 2001-08-20 AT AT01965201T patent/ATE386022T1/de active
- 2001-08-20 SI SI200130812T patent/SI1313703T1/sl unknown
- 2001-08-20 CA CA002419279A patent/CA2419279C/en not_active Expired - Fee Related
- 2001-08-20 WO PCT/EP2001/009561 patent/WO2002016321A1/en not_active Ceased
- 2001-08-20 HR HR20030125A patent/HRP20030125B1/xx not_active IP Right Cessation
- 2001-08-20 RS YUP-130/03A patent/RS51467B/sr unknown
- 2001-08-20 AU AU8589401A patent/AU8589401A/xx active Pending
- 2001-08-20 BR BR0113348-9A patent/BR0113348A/pt not_active Application Discontinuation
- 2001-08-20 IL IL15425401A patent/IL154254A0/xx not_active IP Right Cessation
- 2001-08-20 CZ CZ20030492A patent/CZ303319B6/cs not_active IP Right Cessation
- 2001-08-20 PL PL361387A patent/PL204215B1/pl unknown
- 2001-08-20 EG EG20010906A patent/EG24293A/xx active
- 2001-08-20 HU HU0301548A patent/HU229802B1/hu not_active IP Right Cessation
- 2001-08-20 DK DK01965201T patent/DK1313703T3/da active
- 2001-08-20 KR KR1020037002485A patent/KR100589991B1/ko not_active Expired - Fee Related
- 2001-08-20 PT PT01965201T patent/PT1313703E/pt unknown
- 2001-08-20 AU AU2001285894A patent/AU2001285894B2/en not_active Ceased
- 2001-08-20 EP EP01965201A patent/EP1313703B1/en not_active Expired - Lifetime
-
2003
- 2003-01-31 ZA ZA200300894A patent/ZA200300894B/en unknown
- 2003-02-19 NO NO20030781A patent/NO324941B1/no not_active IP Right Cessation
- 2003-02-20 EC EC2003004489A patent/ECSP034489A/es unknown
- 2003-02-21 MA MA27052A patent/MA26947A1/fr unknown
-
2008
- 2008-05-08 CY CY20081100485T patent/CY1107937T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023895L (no) | Anilin-avledete ligander for thyroid-reseptoren | |
| IL161439A0 (en) | Cannabinoid receptor ligands | |
| PL364624A1 (en) | Cannabinoid receptor ligands | |
| MA26621A1 (fr) | Composition pour aerosols pharmaceutiques | |
| MXPA03005257A (es) | Composiciones frarmaceuticas de un agonista del receptor de nmda. | |
| FR2814446B1 (fr) | Pot distributeur pour produit de consistance visqueuse | |
| DK1068202T3 (da) | 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister | |
| FI20002039A0 (fi) | Ligandimodifioidut selluloosatuotteet | |
| PL369544A1 (en) | Pyridine derivatives as nmda receptor ligands | |
| MA26947A1 (fr) | Prodrogues pour ligands recepteurs de nmda | |
| DK1121305T3 (da) | Emballagematerialer til sæbe | |
| FR2806677B1 (fr) | Unite de reglage pour appui-tete | |
| EP1140829A4 (en) | CONTRAST AGENT FOR ANGIOGRAPHY | |
| NO20003593D0 (no) | Emballasje for muslinger | |
| FR2828159B1 (fr) | Wagonnet pour four | |
| FR2794106B1 (fr) | Conditionnement pour volailles | |
| UA4303S (uk) | Упаковка для продукції хадо | |
| FR2811312B1 (fr) | Ensemble deboucheur-reboucheur pour bouteille | |
| FI4675U1 (fi) | Pakkaus levymäisiä tuotteita varten | |
| ES1046034Y (es) | Dispensador antihumedad de productos pulverulentos. | |
| ES1046343Y (es) | Cazo perfeccionado para medida de productos. | |
| UA33971A (uk) | Пристрій для формування виробів з бетонних сумішей | |
| FR2816413B1 (fr) | Microscope pour objets diffractants | |
| UA2861S (uk) | Форма для виливання супозиторіїв | |
| UA5417S (uk) | Упаковка для продукції хадо |